Cover Image
市場調查報告書

全球帕金森氏症治療藥市場

Global Parkinson's Disease Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 278974
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
全球帕金森氏症治療藥市場 Global Parkinson's Disease Market 2014-2018
出版日期: 2014年07月23日 內容資訊: 英文 97 Pages
簡介

全球帕金森氏症治療藥市場,預計2013年∼2018年以CAGR3.32%成長。

本報告提供全球帕金森氏症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 市場區隔:各作用機制

  • 抗膽鹼藥
  • β腎上腺素隔斷藥
  • COMT抑制劑
  • 多巴胺致效劑
  • 多巴胺補充劑
  • MAO-B抑制劑
  • 其他

第8章 地區區分

第9章 購買標準

第10章 推動市場成長要素

第11章 推動因素與其影響

第12章 市場課題

第13章 推動因素與課題的影響

第14章 市場趨勢

第15章 趨勢與其影響

第16章 業者情勢

  • 競爭模式
  • 市場佔有率分析

第17章 後期開發品候補

  • 後期開發品候補的主要資訊
  • 後期開發品候補的中止開發

第18章 其他卓越供應商

第19章 主要供應商分析

  • 產業概要、產業策略、SWOT分析等
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Novartis
    • Teva

第20章 相關報告

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR3862

About Parkinson's Disease

Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances.

TechNavio's analysts forecast the Global Parkinson's Disease market will grow at a CAGR of 3.32 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Parkinson's Disease market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to provide symptomatic relief in Parkinson's disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Parkinson's Disease market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Parkinson's Disease Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Parkinson's Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors

  • Abbvie Inc.
  • Akorn Inc.
  • Astellas Pharma Inc.
  • Desitin Arzneimittel GmbH
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Kyowa Hakko Kirin
  • Merck & Co. Inc.
  • Orion Corp.
  • STADA Arzneimittel AG
  • UCB Inc.
  • US WorldMeds LLC
  • Valeant Pharmaceuticals International Inc.

Key Market Driver

  • Increase in Patient Population

For a full, detailed list, view our report.

Key Market Challenge

  • Generic Erosion

For a full, detailed list, view our report.

Key Market Trend

  • Reformulation of Marketed Drugs

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by MOA

  • 07.1.1. Anticholinergics
  • 07.1.2. Beta-Adrenergic Antagonists
  • 07.1.3. COMT Inhibitors
  • 07.1.4. Dopamine Agonists
  • 07.1.5. Dopamine Replenishers
  • 07.1.6. MAOB Inhibitors
  • 07.1.7. Others

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Market Share Analysis 2013
    • 16.2.1. Novartis
    • 16.2.2. Boehringer
    • 16.2.3. Teva
    • 16.2.4. GlaxoSmithKline

17. Key Late-Stage Pipeline Candidates

  • 17.1. Key Information for Late-Stage Pipeline Candidates
    • 17.1.1. ABT-SLV187
    • 17.1.2. BIA 9-1067
    • 17.1.3. IPX066
    • 17.1.4. KW-6002
    • 17.1.5. NW 1015
    • 17.1.6. OS-320
    • 17.1.7. P2B 001
  • 17.2. Key Late-Stage Discontinued Drug Candidates

18. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Boehringer Ingelheim
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue Segmentation by Business /Products
    • 19.1.6. Sales by Geographical Segmentation
    • 19.1.7. Key Information
    • 19.1.8. SWOT Analysis
    • 19.1.9. Strengths
    • 19.1.10. Weaknesses
    • 19.1.11. Opportunities
    • 19.1.12. Threats
  • 19.2. GlaxoSmithKline
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Pipeline Products
    • 19.2.7. Business Strategy
    • 19.2.8. Key Information
    • 19.2.9. SWOT Analysis
    • 19.2.10. Strengths
    • 19.2.11. Weaknesses
    • 19.2.12. Opportunities
    • 19.2.13. Threats
  • 19.3. Novartis
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. Teva
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2013
    • 19.4.5. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.4.6. Sales by Geography
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis
    • 19.4.10. Strengths
    • 19.4.11. Weakness
    • 19.4.12. Opportunities
    • 19.4.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Parkinson's Disease Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Parkinson's Disease Market Segmentation by MOA
  • Exhibit 4: Anticholinergics Approved for the Treatment of Parkinson's Disease
  • Exhibit 5: Beta-Adrenergic Antagonists Approved for the Treatment of Parkinson's Disease
  • Exhibit 6: COMT Inhibitors Approved for the Treatment of Parkinson's Disease
  • Exhibit 7: Dopamine Agonists Approved for the Treatment of Parkinson's Disease
  • Exhibit 8: Dopamine Replenishers Approved for the Treatment of Parkinson's Disease
  • Exhibit 9: MAOB Inhibitors Approved for the Treatment of Parkinson's Disease
  • Exhibit 10: Some Other Drugs Approved for the Treatment of Parkinson's Disease
  • Exhibit 11: Global Parkinson's Disease Market by Geographical Segmentation 2013
  • Exhibit 12: Geography-wise Segmentation of Novartis' Comtan and Stalevo Sales 2013
  • Exhibit 13: Geography-wise Segmentation of Exelon's Sales in 2013
  • Exhibit 14: Geography-wise Revenue of Requip in 2013 (US$ million)
  • Exhibit 15: Business Segmentation of Boehringer Ingelheim Gmbh
  • Exhibit 16: Net Sales by Business of Boehringer Ingelheim GmbH
  • Exhibit 17: Revenue Segmentation by Business /Products (2013)
  • Exhibit 18: Sales by Geographical Segmentation (2013)
  • Exhibit 19: GlaxoSmithKline Plc: Business Segmentation 2013
  • Exhibit 20: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
  • Exhibit 21: GlaxoSmithKline Plc: Sales by Geography 2013
  • Exhibit 22: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 23: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 24: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 25: Novartis AG: Sales by Geography 2013
  • Exhibit 26: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 27: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
  • Exhibit 28: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 29: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013
Back to Top